Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Atrovent 250 UDVs, 1 ml.
Atrovent UDVs, 2 ml.
| Pharmaceutical Form |
|---|
|
Nebuliser solution. |
Each single dose unit contains 0.025% w/v ipratropium bromide i.e. 250 micrograms in 1 ml and 500 micrograms in 2 ml.
For excipients, see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ipratropium |
Ipratropium is a quaternary ammonium compound with anticholinergic (parasympatholytic) properties. Ipratropium appears to inhibit vagally mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase in intracellular concentration of Ca++, which is caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle. Ca++ release is mediated by the second messenger system consisting of IP3 (inositol triphosphate) and DAG (diacylglycerol). |
| List of Excipients |
|---|
|
Sodium chloride |
Polyethylene unit dose vials containing either 1 ml or 2 ml of solution.
Pack sizes of 10, 20, 30, 50, 60, 80, 100, 120, 150, 200, 300, 500 and 1000.
Not all pack sizes may be marketed.
Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
PL 0015/0108
27 August 1986 / 23 December 2005
| Drug | Countries | |
|---|---|---|
| ATROVENT | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, Tunisia, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
